Premium
Association between serum levels of vitamin D with body fat mass, fasting glucose and lipid profile in patients with osteogenesis imperfecta
Author(s) -
Peters Barbara Santarosa Emo,
LazarettiCastro Marise,
Hayashi Lilian F.,
Costa Aline Vasques,
Martini Lígia Araújo
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1053.14
Subject(s) - medicine , endocrinology , body mass index , lipid profile , vitamin d and neurology , type 2 diabetes , cholesterol , osteogenesis imperfecta , chemistry , diabetes mellitus , pathology
Aim Evaluate the associations between serum levels of 25(OH)D with body fat mass, glicidic and lipid profile in patients with Osteogenesis Imperfecta (OI). Methods Thirty (30) patients, 16 with OI type I and 14 with OI type III, mean age 26.2 (10.8) years old, were selected at the Bone Fragility outpatient clinic of the Federal University of São Paulo. Weight, height, body mass index (BMI) and fat mass (%FM) (DEXA) were evaluated. Serum levels of 25(OH)D3 were measured by chemiluminescence assay; fasting glucose, total cholesterol, HDL and triglycerides by enzymatic colorimetric assay, and plasma insulin by chemiluminescence detection. Results Excess %FM was present in 66.7% of subjects. Only 6.7% of OI patients presented high levels of total cholesterol and triglycerides. All patients presented normal levels of fasting glucose (86.4 ± 8.8 mg/dL) and plasma insulin (7.4 ± 4.9 μUI/mL). The mean serum levels of 25(OH)D3 was 66.5 ± 19.0 nmol/L. No statistical significant difference in biochemical parameters between subjects of OI type I and III were observed. An inverse correlation between serum levels of 25(OH)D3 and fasting glucose was observed (r: −0.652; p:0.03). In OI patients type III there was an inverse correlation between 25(OH)D3 and %FM (r: −0.566; P:0.04). Conclusion There were associations between 25(OH)D with body fat mass and fasting glucose in patients with OI. Grant Funding Source : Fundação de Amparo à Pesquisa do Estado de São Paulo